Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study

Neurocrine Biosciences (NASDAQ: NBIX ) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week